IMR Press / FBL / Volume 18 / Issue 3 / DOI: 10.2741/4170

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Cerebrospinal fluid biomarkers of Alzheimer’s disease in healthy elderly

Show Less
1 Center for Brain Health, 145 East 32nd Street, 5th floor. New York, NY 10016, USA
Front. Biosci. (Landmark Ed) 2013, 18(3), 1150–1173;
Published: 1 June 2013
(This article belongs to the Special Issue The polyhedral aspects of dementia)

Numerous studies have shown that Alzheimer’s Disease (AD) pathology begins before the onset of clinical symptoms. Because therapies are likely to be more effective if they are implemented early in the disease progression, it is necessary to identify reliable biomarkers to detect AD pathology in the early stages of the disease, ideally in presymptomatic individuals. Recent research has identified three candidate cerebrospinal fluid (CSF) biomarkers that reflect AD pathology: amyloid beta, total tau protein (t-tau), and tau protein phosphorylated at ADspecific epitopes (p-tau). They are useful in supporting the AD diagnosis and have predictive value for AD when patients are in the stage of mild cognitive impairment (MCI). However, their predictive utility in cognitively healthy subjects is still being evaluated. We conducted a review of studies published between 1993 and 2011 and summarized their findings on the role of CSF biomarkers for AD in healthy elderly.

Alzheimer’s disease
Cerebrospinal fluid
Amyloid beta
Phosphorylated tau
Normal populations
Back to top